MENLO PARK, Calif., March 19, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2") today announced that two abstracts related to the ENGULF study and the Hēlo® Platform have been accepted as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results